Anagram Therapeutics, Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
Anagram Therapeutics, Inc. is a clinical-stage biotechnology company based in Natick, Massachusetts. It concentrates on gastrointestinal diseases, applying proprietary enzyme technologies to address malabsorption and nutrient metabolism disorders, including conditions such as cystic fibrosis and other rare diseases. Its lead candidate, ANG003, targets malabsorption and exocrine pancreatic insufficiency and represents a broad-spectrum enzyme replacement approach. In addition to ANG003, the company seeks to advance a pipeline addressing how these disorders disrupt the body’s ability to process fats, sugars, proteins, vitamins, and other nutrients. In 2023, Anagram expanded its collaboration with ATUM to pursue orally delivered enzyme therapies for malabsorption and nutrient metabolism disorders. The organization operates within the biotechnology research sector and maintains a relatively small to mid-sized team.